First 3 years of the National AIDS Clearinghouse.

The National AIDS Clearinghouse is an information service provided by the Centers for Disease Control. The Clearinghouse was established in 1987 to respond to increasing numbers of public and professional inquiries, to disseminate accurate information, and to make referrals to local sources of information and assistance. Four data bases--Resources and Services Database containing information about more than 16,000 organizations that provide counseling and testing for human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) and other education and prevention services; Educational Materials Database containing more than 8,000 individual, hard-to-find educational materials; Funding Database; and the AIDS Clinical Trial Information Service (ACTIS) Database--are searched by information specialists to respond to more than 45,000 requests annually for information from a variety of health professionals, organizations, and the general public. Between 1987 and 1991, the Clearinghouse disseminated more than 60 million copies of publications related to HIV and AIDS. Information and education remain the most critical tools for the prevention of HIV infection, and the National AIDS Clearinghouse provides an essential element for the dissemination of education and prevention information.

Tribal differences in diabetes: prevalence among American Indians in New Mexico.

The prevalence of diagnosed diabetes among American Indians in New Mexico with varied genetic and cultural backgrounds is reported. Utilizing community-based registries, the prevalence in persons ages 35 years and older ranged from 9.8 percent among Jicarilla Apache Indians to 28.2 percent among Zuni Indians. All rates were significantly higher than the U.S. rate of 5.3 percent for the same age group. In addition, in three of the five tribal groups examined, the rates of diagnosed diabetes in Indians less than 35 years of age (range from 0.5 percent to 1.3 percent) were significantly higher than the U.S. rate of 0.4 percent for the same age group. The prevalence rates of diagnosed diabetes found in this study of American Indians in New Mexico were intermediate between those for the United States as a whole and the Pima Indians of southern Arizona. Reasons for the variations and the relative contribution of obesity, fitness, or genetic risk in the development of diabetes need further study.

Lower-extremity amputation in people with diabetes. Epidemiology and prevention.

The age-adjusted rate of lower-extremity amputation (LEA) in the diabetic population is approximately 15 times that of the nondiabetic population. Over 50,000 LEAs were performed on individuals with diabetes in the United States in 1985. Among individuals with diabetes, peripheral neuropathy and peripheral vascular disease (PVD) are major predisposing factors for LEA. Lack of adequate foot care and infection are additional risk factors. Several large clinical centers have experienced a 44-85% reduction in the rate of amputations among individuals with diabetes after the implementation of improved foot-care programs. Programs to reduce amputations among people with diabetes in primary-care settings should identify those at high risk; clinically evaluate individuals to determine specific risk status; ensure appropriate preventive therapy, treatment for foot problems, and follow-up; provide patient education; and, when necessary, refer patients to specialists, including health-care professionals for diagnostic and therapeutic interventions and shoe fitters for proper footwear. Programs should monitor and evaluate their activities and outcomes. Many issues related to the etiology and prevention of LEAs require further research.

An epidemiological model for diabetes mellitus in the United States: five major complications.

Diabetes mellitus affects almost 5.5 million Americans each year. An estimated additional 5 million individuals may have diabetes, but remain undetected. Individuals with diabetes are at high risk for the development of micro- and macrovascular disease, diabetic coma and adverse outcome of pregnancy. The rate at which these complications develop are now partially identifiable for the United States. For 5 potentially preventable complications (retinopathy, adverse outcome of pregnancy, vascular disease, nephropathy and diabetic coma) the morbidity and mortality rates can now be calculated. There exist 50,000 cases of blindness due to diabetes with an additional 5800 new cases each year. Adverse outcome of diabetic pregnancy occurs in over 18,000 births each year, with as many as 4500 related perinatal deaths. Each year 40,000 diabetics are required to have a lower extremity amputation. Of the already 70,000 diabetics who have had an amputation, 25,000 will die this year. End stage renal disease affects 4000 diabetics each year. During the same time period, of the 7500 existing cases of end stage renal disease, 2000 will result in mortality cases. Diabetic coma (DKA and HHNK) accounts for 67,400 hospitalizations and results in 3600 deaths each year. Together these complications and those associated with cardiovascular disease account for 323,000 deaths with diabetes as the underlying or contributing cause in the United States.

An epidemiologic model for diabetes mellitus: incidence, prevalence, and mortality.

An epidemiologic model is developed to describe the incidence, prevalence, and mortality of diabetes. Available data are reviewed, analyzed, and applied to the model. The model provides a framework for understanding diabetes on a population basis, and is useful in identifying needs and facilitating health care planning.

Reimbursement issues in diabetes.

Third-party reimbursement for outpatient education services and for new health care technologies in diabetes is an issue of concern to educators, administrators, and others in the diabetes health care system. Reimbursement for outpatient education has been obtained from 11 Blue Cross/Blue Shield plans in nine states, six commercial insurance companies in four states, Medicare in five states, and Medicaid in one state. Despite these successes, third-party payers still must be approached on an individual basis. We review approaches taken by different states and diabetes control programs and make recommendations on how to request third-party reimbursement for outpatient education services. Third-party reimbursement of diabetes-related technologies/services and equipment is found to be dependent on the type of coverage the individual has, the state in which he or she is located, and the item or procedure covered. Many third-party payers do not have stated policies on reimbursement of a particular piece of equipment such as the insulin pump, or they do not have consistent, well-communicated standards for determining coverage.

An approach to the prevention of blindness in diabetes.

Diabetic eye disease is the leading cause of new cases of legal blindness in American adults under the age of 65 yr. Diabetic persons are at risk for visual loss due to diabetic retinopathy, glaucoma, and cataracts. Better understanding of the natural histories of these complications and recent advances in treatment have provided a rationale for developing an approach to prevent visual loss. This approach requires that diabetic patients who are at high risk for visual loss, and not under the care of ophthalmologists, be systematically screened, referred, and treated.

Epidemiologic characteristics of mortality from diabetes with acidosis or coma, United States, 1970-78.

Deaths due to diabetes with acidosis or coma (DAC) in the United States from 1970 through 1978 were analyzed to determine epidemiologic characteristics associated with mortality likely to be due to diabetic ketoacidosis (DKA), a complication of diabetes mellitus considered largely preventable. Annual age-adjusted rates for DAC deaths decreased during the study period, and the secular trend was significant in all regional, race, and sex groups examined. General population-based mortality rates increased linearly with age, were higher in non-Whites than in Whites among persons aged greater than 14, were higher in females, and increased significantly with age in both races and both sexes. By region, rates were lowest in the West. DAC mortality rates specific to estimated diabetic populations decreased annually from 1970 to 1978 in all race and sex groups, and were highest at age greater than or equal to 65, but did not show significant linear increases with age, except in non-Whites. These results indicate declining secular trends, as well as age, race, sex, and regional differences in the risk of such deaths. Further studies are warranted to determine factors contributing to these differences.

The epidemiology of lower extremity amputations in diabetic individuals.

The Diabetes Control Activity has established diabetes control programs in 20 states. Each has investigated the extent and nature of diabetes morbidity within its state by means of a descriptive analysis of selected health status indicators. Data from six states are included: 100% of hospital discharges from Rhode Island, South Carolina, and Maine and approximately 50% from Minnesota, Illinois, and Ohio were pooled to provide a profile of lower extremity amputations (LEA) in diabetic individuals. The purposes of this study were to identify diabetic persons at high risk of amputation for targeting preventive programs as well as to establish a baseline for monitoring trends over time. Discharge data provided by hospital abstracting services were examined for 1976-1978. Results indicate that 45% of all LEAs are performed on patients with diabetes. An age-adjusted LEA rate of 59.7/10,000 diabetic individuals was computed. Diabetes-related amputation rates increase with age and are higher in males. The overwhelming majority of LEAs are either toe or above the knee, with few performed on the foot. The relative risk of LEAs for the diabetic compared with the nondiabetic population is highest in the under-45 age group (28), although the attributable risk is highest in the older population (91.5/10,000 diabetic individuals). Overall, diabetic persons have a 15 times higher risk of LEA than nondiabetic individuals.